Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Erector Spinae Plane Blocks for Pain Control After Total Laparoscopic Hysterectomy

12 novembre 2026 aggiornato da: Hande Gurbuz

Effects of Erector Spinae Plane Block and Deep Erector Spinae Plane Block on Postoperative Pain Management in Total Laparoscopic Hysterectomy

This study will compare two nerve block techniques for pain relief after total laparoscopic hysterectomy, a minimally invasive operation to remove the uterus. Both techniques involve injecting a local anesthetic near muscles of the lower back, but the injections are given at different depths.

Women aged 18 to 65 years who are scheduled for this surgery will be randomly assigned to one of three groups: erector spinae plane block, deep erector spinae plane block, or no nerve block. The nerve blocks will be performed on both sides of the lower back after surgery. All participants will receive standard pain medication.

The main aim is to compare pain scores one hour after surgery. The study will also assess pain during the first 24 hours, opioid pain medication use, the time until additional pain relief is needed, nausea and vomiting, time to hospital discharge, patient satisfaction, and quality of recovery.

Panoramica dello studio

Descrizione dettagliata

This single-center, prospective, randomized controlled study will compare ultrasound-guided bilateral erector spinae plane block and deep erector spinae plane block with a control group receiving no block in women undergoing total laparoscopic hysterectomy under general anesthesia.

Participants will be allocated to three groups using computer-generated randomization. Blocks will be performed postoperatively in the recovery unit at the L1 vertebral level. In the erector spinae plane block group, the injection will be administered between the erector spinae muscle and the transverse process. In the deep erector spinae plane block group, the injection will be administered deep to the transverse process, in the plane between the erector spinae and psoas muscles. Both block groups will receive 20 mL of 0.25% bupivacaine on each side. The control group will receive no block.

All groups will receive standardized general anesthesia and perioperative multimodal analgesia. Intravenous meperidine at 0.25 mg/kg will be administered as rescue analgesia when the numerical rating scale pain score exceeds 3.

An anesthesiologist blinded to group allocation will assess pain at rest and during movement. Baseline pain scores (0 minutes) will be recorded before block administration. Subsequent pain assessments in the block groups will be timed from completion of bilateral block administration. In the control group, an equivalent reference time will be established in the postoperative recovery unit, and the same assessment schedule will be followed. Postoperative assessments will include pain scores, opioid consumption, rescue analgesic requirements, nausea and vomiting, discharge time, patient satisfaction, and quality of recovery using the Quality of Recovery-15 questionnaire.

Tipo di studio

Interventistico

Iscrizione (Stimato)

87

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Hande Gurbuz, Prof, MD, PhD
  • Numero di telefono: +90 533 651 56 50
  • Email: handegrbz@gmail.com

Luoghi di studio

    • Bursa
      • Bursa, Bursa, Turchia (Türkiye), 16110
        • University of Health Sciences, Bursa City Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Female patients aged 18 to 65 years.
  • Scheduled for elective total laparoscopic hysterectomy.
  • American Society of Anesthesiologists (ASA) physical status I, II, or III.
  • Provision of written informed consent.

Exclusion Criteria:

  • ASA physical status IV or higher.
  • Inability to cooperate with pain assessment because of cognitive impairment, a psychiatric condition, or inability to understand Turkish.
  • Known allergy to local anesthetics or opioids.
  • Body mass index greater than 35 kg/m².
  • Infection at the planned injection site.
  • Neurological deficits.
  • Alcohol or drug dependence.
  • Known or suspected coagulopathy.
  • Severe hepatic, cardiac, or renal disease.
  • Emergency surgery or repeat surgery.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Erector Spinae Plane Block

Participants will receive an ultrasound-guided bilateral erector spinae plane block at the L1 vertebral level in the postoperative recovery unit. On each side, 20 mL of 0.25% bupivacaine will be injected into the plane between the erector spinae muscle and the transverse process. Participants will also receive standardized perioperative multimodal analgesia and rescue analgesia as needed.

Ultrasound-guided bilateral erector spinae plane block performed at the L1 vertebral level in the postoperative recovery unit. Following confirmation of needle placement and negative aspiration, 20 mL of 0.25% bupivacaine without adjuvants will be injected between the erector spinae muscle and the transverse process on each side.

Sperimentale: Deep Erector Spinae Plane Block

Participants will receive an ultrasound-guided bilateral deep erector spinae plane block at the L1 vertebral level in the postoperative recovery unit. On each side, 20 mL of 0.25% bupivacaine will be injected into the plane between the erector spinae and psoas muscles, deep to the transverse process. Participants will also receive standardized perioperative multimodal analgesia and rescue analgesia as needed.

Ultrasound-guided bilateral deep erector spinae plane block performed at the L1 vertebral level in the postoperative recovery unit. Following confirmation of needle placement and negative aspiration, 20 mL of 0.25% bupivacaine without adjuvants will be injected into the plane between the erector spinae and psoas muscles, deep to the transverse process, on each side.

Nessun intervento: Control Group

Participants will receive no nerve block. They will receive the same standardized perioperative multimodal analgesia as the two block groups, with rescue analgesia administered as needed.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pain Intensity at Rest at 1 Hour After Block Administration
Lasso di tempo: At 1 hour after block administration or the equivalent reference time in the control group

Pain intensity at rest will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. Assessment will occur 1 hour after completion of bilateral block administration or the equivalent reference time in the control group.

At 1 hour after block administration or the equivalent reference time in the control group

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pain Intensity During Movement at 1 Hour After Block Administration
Lasso di tempo: At 1 hour after Block Administration

Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable). Higher scores indicate greater pain intensity. At 1 hour after block administration or the equivalent reference time in the control group

At 1 hour after Block Administration
Pain Intensity at Rest Before and After Block Administration
Lasso di tempo: At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery

Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable), at baseline (before block administration) and at 15 and 30 minutes and 6, 18, and 24 hours after block administration, with corresponding assessments in the control group. Higher scores indicate greater pain intensity. Scores will be compared between groups at each assessment time point.

At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
Pain Intensity During Movement Before and After Block Administration
Lasso di tempo: At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery

Pain intensity during movement will be assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (the worst pain imaginable), at baseline (before block administration) and at 15 and 30 minutes and 6, 18, and 24 hours after block administration, with corresponding assessments in the control group. Higher scores indicate greater pain intensity. Scores will be compared between groups at each assessment time point.

At 0, 15, and 30 minutes and 6, 18, and 24 hours after surgery
Cumulative Rescue Opioid Consumption During the First 24 Hours After Surgery
Lasso di tempo: During the first 24 hours after surgery

The total dose of intravenous meperidine administered as rescue analgesia during the first 24 hours after surgery will be recorded in milligrams. Rescue analgesia will be administered at a dose of 0.25 mg/kg when the numerical rating scale (NRS) pain score exceeds 3. Higher consumption indicates a greater requirement for rescue opioid analgesia.

During the first 24 hours after surgery
Time to First Rescue Analgesia
Lasso di tempo: From the end of surgery to the first administration of rescue analgesia, up to 24 hours

The time from the end of surgery to the first administration of rescue analgesia will be recorded in minutes. Intravenous meperidine at 0.25 mg/kg will be administered when the numerical rating scale (NRS) pain score exceeds 3. Participants who do not receive rescue analgesia during the first 24 hours will be censored at 24 hours.

From the end of surgery to the first administration of rescue analgesia, up to 24 hours
Postoperative Nausea and Vomiting Severity
Lasso di tempo: During the first 24 hours after surgery

Postoperative nausea and vomiting will be assessed using a five-point scale: 0 = none, 1 = mild nausea, 2 = moderate nausea, 3 = one episode of vomiting, and 4 = more than one episode of vomiting. Higher scores indicate greater severity.

During the first 24 hours after surgery
Quality of Recovery at 24 Hours After Surgery
Lasso di tempo: Preoperatively and at 24 hours after surgery

Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The questionnaire contains 15 items, with a total score ranging from 0 to 150. Higher scores indicate better quality of recovery. The questionnaire will be administered preoperatively and at 24 hours after surgery.

Preoperatively and at 24 hours after surgery

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Hande Gurbuz, Prof, MD, PhD, University of Health Sciences, Bursa School of Medicine, Bursa City Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

There is currently no plan to share individual participant data with other researchers.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi